ELK GROVE VILLAGE, Ill., April 18, 2024 /PRNewswire/ -- Orsini Specialty Pharmacy has been selected by Edenbridge Pharmaceuticals as the preferred specialty pharmacy partner for the distribution of Yargesa (miglustat) capsules, 100mg. YARGESA is a glucosylceramide synthase inhibitor indicated for the treatment of adult patients with Type 1 Gaucher disease for whom enzyme replacement therapy is not a therapeutic option.
Orsini selected as the exclusive specialty pharmacy for WAINUA™
ELK GROVE VILLAGE, Ill., Nov. 20, 2023 /PRNewswire/ -- Orsini Specialty Pharmacy has been selected by Takeda Pharmaceuticals as the exclusive specialty pharmacy partner for ADZYNMA (ADAMTS13, recombinant-krhn), approved by the FDA on November 9, 2023, for prophylactic or on demand enzyme replacement therapy (ERT) in adult and pediatric patients with congenital thrombotic thrombocytopenic purpura (cTTP). ADZYNMA is the first and only FDA-approved recombinant ADAMTS13 (rADAMTS13) enzyme replacement therapy for people with cTTP designed to address the root cause of the condition, an ADAMTS13 enzyme deficiency. ADZYNMA is expected to be commercially available in December 2023. Read the Full Prescribing Information here.
ELK GROVE VILLAGE, Ill., July 11, 2023 /PRNewswire/ -- Orsini Specialty Pharmacy, a leading independent specialty pharmacy focused on rare diseases and gene therapies, announced today that BioMarin Pharmaceutical has selected it to dispense ROCTAVIAN™ (valoctocogene roxaparvovec-rvox). ROCTAVIAN is the first gene therapy for the treatment of severe Hemophilia A. For more information about ROCTAVIAN, see the Full Prescribing Information. Orsini's dedicated Gene Therapy Care team is trained and ready to accept new patients.
ELK GROVE VILLAGE, III., June 27, 2023 /PRNewswire/ -- Orsini Specialty Pharmacy, a leading independent specialty pharmacy focused on rare diseases and gene therapies, announced today that Sarepta Therapeutics, Inc. has selected the company as one of its limited distribution providers of ELEVIDYS (delandistrogene moxeparvovec-rokl). ELEVIDYS is the first gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with Duchenne muscular dystrophy (DMD) with a confirmed mutation in the DMD gene and is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the DMD gene.
ELK GROVE VILLAGE, Ill., June 22, 2023 /PRNewswire/ -- Orsini Specialty Pharmacy announced today that Aimmune Therapeutics has selected it as a limited distribution partner for VOWST™ (fecal microbiota spores, live – brpk). VOWST is indicated to prevent the recurrence of Clostridioides difficile infection (CDI) in individuals 18 years of age and older following antibacterial treatment for recurrent CDI (rCDI). Limitation of Use: VOWST is not indicated for the treatment of CDI. See full Prescribing Information and Patient Information, or visit www.VOWSThcp.com to learn more about VOWST.
ELK GROVE VILLAGE, Ill., May 23, 2023 /PRNewswire/ -- Orsini Specialty Pharmacy, a leading independent specialty pharmacy focused on rare diseases and gene therapies, announced today that Krystal Biotech has selected it as part of the limited specialty pharmacy network for VYJUVEK™ (beremagene geperpavec-svdt), a topical gene therapy for the treatment of Dystrophic Epidermolysis Bullosa (DEB). For more information about VYJUVEK, see the Full Prescribing Information or https://vyjuvek.com.
ELK GROVE VILLAGE, Ill., Feb. 16, 2023 /PRNewswire/ -- Orsini Specialty Pharmacy today announced that the company earned URAC's prestigious designation as a Rare Disease Pharmacy Center of Excellence. URAC is the independent leader in promoting healthcare quality through accreditation, certification, and measurement. Their Center of Excellence designation recognizes specialty pharmacies that demonstrate a commitment to quality health services, patient safety, and improved outcomes for patients living with rare diseases.
ELK GROVE VILLAGE, Ill., Dec. 12, 2022 /PRNewswire/ -- Orsini Specialty Pharmacy announced today that the company's Board of Directors has appointed Brandon Tom as the new Chief Executive Officer. A seasoned leader with over 15 years of industry experience, most recently as Vice President and General Manager of Biologics by McKesson, Tom will succeed Mike Fieri, Founder and former CEO of Orsini Specialty Pharmacy. Fieri will transition to Vice Chairman of Orsini and will continue to lead the company's pursuit of key strategic and growth initiatives.